context human papillomavirus hpv infection is estimated to be the most common sexually transmitted infectionbaseline population prevalence data for hpv infection in the united states before widespread availability of a prophylactic hpv vaccine would be usefulobjective to determine the prevalence of hpv among females in the united statesdesign setting and participants the national health and nutrition examination survey nhanes uses a representative sample of the us noninstitutionalized civilian populationfemales aged 14 to 59 years who were interviewed at home for nhanes 20032004 were examined in a mobile examination center and provided a selfcollected vaginal swab specimenswabs were analyzed for hpv dna by l1 consensus polymerase chain reaction followed by typespecific hybridizationdemographic and sexual behavior information was obtained from all participantsmain outcome measures hpv prevalence by polymerase chain reactionresults the overall hpv prevalence was 268 95 confidence interval ci 233309 among us females aged 14 to 59 years n  1921hpv prevalence was 245 95 ci 196305 among females aged 14 to 19 years 448 95 ci 363553 among women aged 20 to 24 years 274 95 ci 219342 among women aged 25 to 29 years 275 95 ci 208364 among women aged 30 to 39 years 252 95 ci 197322 among women aged 40 to 49 years and 196 95 ci 143268 among women aged 50 to 59 yearsthere was a statistically significant trend for increasing hpv prevalence with each year of age from 14 to 24 years p001 followed by a gradual decline in prevalence through 59 years p  06hpv vaccine types 6 and 11 lowrisk types and 16 and 18 highrisk types were detected in 34 of female participants hpv6 was detected in 13 95 ci 0823 hpv11 in 01 95 ci 00303 hpv16 in 15 95 ci 0926 and hpv18 in 08 95 ci 0415 of female participantsindependent risk factors for hpv detection were age marital status and increasing numbers of lifetime and recent sex partnersconclusions hpv is common among females in the united statesour data indicate that the burden of prevalent hpv infection among females was greater than previous estimates and was highest among those aged 20 to 24 yearshowever the prevalence of hpv vaccine types was relatively low